Collective Family Office’s ImmunityBio IBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.38M Buy
157,200
+4,693
+3% +$35.5K 0.28% 66
2026
Q1
$1.17M Sell
152,507
-4,323
-3% -$29.6K 0.26% 67
2025
Q4
$311K Sell
156,830
-4,450
-3% -$10.1K 0.07% 133
2025
Q3
$397K Buy
161,280
+18,900
+13% +$48.7K 0.1% 121
2025
Q2
$376K Buy
142,380
+38,210
+37% +$103K 0.1% 124
2025
Q1
$314K Buy
104,170
+15,340
+17% +$46.5K 0.08% 129
2024
Q4
$227K Buy
88,830
+9,467
+12% +$39.4K 0.06% 152
2024
Q3
$295K Buy
79,363
+9,008
+13% +$41.7K 0.08% 148
2024
Q2
$445K Buy
+70,355
New +$464K 0.13% 117

Other funds holding IBRX

Collective Family Office's IBRX Position: Q2 2026 in Review

Collective Family Office increased its ImmunityBio (IBRX) stake by 3.1% in Q2 2026, buying an estimated $35.5K and bringing the position to 157,200 shares worth $1.38M. The position accounts for 0.28% of the portfolio, ranked #66.

Collective Family Office first reported a position in IBRX in Q2 2024 and has held it in 9 quarters since. 78 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Collective Family Office held 157,200 shares of ImmunityBio worth $1.38M as of Q2 2026.
  • Collective Family Office bought 4,693 ImmunityBio shares in Q2 2026, an estimated $35.5K.
  • ImmunityBio made up 0.28% of Collective Family Office's portfolio in Q2 2026, its #66 holding.
  • Collective Family Office first reported a position in ImmunityBio in Q2 2024 and has held it in 9 quarters since.
  • 78 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Collective Family Office's 13F filing for Q2 2026, filed 2 Jul 2026.